Patients on current medical treatment for WD for more than 12 months had lower sCD163 levels compared with those treated for less than 12 months (2.5 (0.9–9.6) mg/L vs. 3.5 (1.7–24.9) mg/L, p = 0.02) (Fig. 3). The gene discussed is CD163; the disease is Wilson disease.